Drugs / Cell Sense
Cell Sense
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02921373 | Jul 2019 → Jun 2022 | — | Gregory A. Dekaban | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cell Sense | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02921373 ↗ |
| Known as | 19F Cell Sense | “GMP grade 19F Cell Sense imaging agent.” NCT02921373 ↗ |
| Known as | CS-1000 | “The cell tracing agent Cell Sense (CS-1000) is an inert, non-metabolizable tracer.” NCT02921373 ↗ |
| Modality | Diagnostic / imaging agent | “Detection of cells is accomplished with an inert imaging agent containing the MRI sensitive fluorine-19 (19F) nuclei.” NCT02921373 ↗ |